<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17393" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alpha-Adrenergic Receptors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Taylor</surname>
            <given-names>Bryce N.</given-names>
          </name>
          <aff>Lincoln Memorial Un - DeBusk College OM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bryce Taylor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17393.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The indication for the use of an alpha-receptor modifying medication depends on which receptor is the target: the alpha-1 receptor or the alpha-2 receptor. Further, when administering a pharmacologic agent, it can exert either agonistic or antagonistic activity on the alpha receptors. This activity reviews the various alpha receptors and examines the types of agents that can act upon these receptors to alter the physiologic response for therapeutic effect.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the two predominant types of alpha-adrenergic receptors.</p></list-item><list-item><p>Describe the effects of agonistic and antagonistic activity on the various alpha receptors.</p></list-item><list-item><p>Summarize the potential adverse effects for each type of alpha agonist or antagonist medication class.</p></list-item><list-item><p>Explain how knowledge of alpha-receptor physiology can help improve care coordination amongst the interprofessional team.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17393&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17393">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17393.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The indication for the use of an alpha-adrenergic receptor modifying medication depends on which receptor is the target: the alpha-1 receptor or the alpha-2 receptor. Alpha-1 receptors bind catecholamines including, both epinephrine and norepinephrine. In instances in which there is hypoperfusion secondary to decreased cardiac output or decreased systemic vasculature resistance, alpha-1 receptors become stimulated. &#x000a0;It is worth noting that these compounds are not purely selective for the alpha receptor, and often engage beta-adrenergic receptors as well.&#x000a0;The use of alpha-1 agonists is common in all types of shock, cardiopulmonary resuscitation, and heart failure decompensation.<xref ref-type="bibr" rid="article-17393.r1">[1]</xref>&#x000a0; Alpha-1 agonists, such as phenylephrine, are also used to treat upper airway congestion as stimulating the receptor leads to a decreased mucus secretion.<xref ref-type="bibr" rid="article-17393.r2">[2]</xref> Alpha-antagonists, colloquially known as alpha-blockers, work in the peripheral vasculature and inhibit the uptake of catecholamines in smooth muscle cells resulting in vasodilation and blood pressure lowering.&#x000a0;Alpha-antagonists, including doxazosin, prazosin, and phentolamine - are primarily used in the treatment of hypertension and urinary&#x000a0;retention.<xref ref-type="bibr" rid="article-17393.r3">[3]</xref>&#x000a0;</p>
        <p>Alpha-blockers have significant use in the setting of pre-operative pheochromocytoma care.<xref ref-type="bibr" rid="article-17393.r4">[4]</xref> Alpha-blockers are also used off-label for the treatment of post-traumatic stress disorder (PTSD).<xref ref-type="bibr" rid="article-17393.r5">[5]</xref> Alpha-2 stimulation reduces the sympathetic outflow from the vasomotor center centrally and increases vagal tone. Peripheral presynaptic alpha-2 receptors may also reduce sympathetic tone.&#x000a0;Alpha-2 agonists, including clonidine and guanfacine - are used as anti-hypertensives, as well.<xref ref-type="bibr" rid="article-17393.r6">[6]</xref>&#x000a0; Both clonidine and guanfacine are used for behavior modification in children with attention deficit disorder, as well as in adults with PTSD as well.<xref ref-type="bibr" rid="article-17393.r7">[7]</xref><xref ref-type="bibr" rid="article-17393.r8">[8]</xref>&#x000a0;</p>
        <p>
<bold>Alpha-1 Agonists</bold>
</p>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <p>
<bold>Oral Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Midodrine
<list list-type="bullet"><list-item><p>Treatment of symptomatic orthostatic hypotension</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Topical Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Naphazoline/naphazoline-pheniramine
<list list-type="bullet"><list-item><p>Topical ocular vasoconstriction</p></list-item><list-item><p>Use for the relief of redness in the eye/itching (pheniramine)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Phenylephrine
<list list-type="bullet"><list-item><p>Dilate pupils (ophthalmic)</p></list-item><list-item><p>Temporary relief of nasal congestion due to the common cold or allergic rhinitis (nasal)</p></list-item><list-item><p>Used in the treatment of hemorrhoids (rectal/topical)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Xylometazoline
<list list-type="bullet"><list-item><p>Temporary relief of nasal and nasopharyngeal mucosal congestion</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Phenylephrine
<list list-type="bullet"><list-item><p>Hypotension/shock/cardiogenic shock</p></list-item><list-item><p>Hypotension during anesthesia: vasoconstrictor in regional analgesia</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Off-label Uses</bold>
</p>
        <p>
<bold>Oral Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Midodrine
<list list-type="bullet"><list-item><p>Refractory ascites<xref ref-type="bibr" rid="article-17393.r9">[9]</xref></p></list-item><list-item><p>Prevention of dialysis-induced hypotension</p></list-item><list-item><p>Hepatorenal syndrome</p></list-item><list-item><p>Vasovagal syndrome</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Topical Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Phenylephrine
<list list-type="bullet"><list-item><p>Topical vasoconstriction in nasal procedures</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Phenylephrine
<list list-type="bullet"><list-item><p>Hypotension in patients with obstructive hypertrophic cardiomyopathy</p></list-item><list-item><p>Priapism</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Alpha-1 Blockers</bold>
</p>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <p>
<bold>Oral Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment for signs and symptoms of benign prostatic hyperplasia (BPH)<xref ref-type="bibr" rid="article-17393.r10">[10]</xref>
<list list-type="bullet"><list-item><p>Alfuzosin</p></list-item><list-item><p>Tamsulosin</p></list-item><list-item><p>Doxazosin</p></list-item><list-item><p>Terazosin</p></list-item><list-item><p>Silodosin</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Management of hypertension; alpha-blockers not recommended as the first-line agents<xref ref-type="bibr" rid="article-17393.r11">[11]</xref>
<list list-type="bullet"><list-item><p>Prazosin</p></list-item><list-item><p>Doxazosin</p></list-item><list-item><p>Terazosin</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Phentolamine
<list list-type="bullet"><list-item><p>Pheochromocytoma: Diagnosis of this condition via the phentolamine blocking test</p></list-item><list-item><p>Extravasation management: prevention of dermal necrosis/sloughing after extravasation of norepinephrine</p></list-item><list-item><p>Local anesthesia reversal: reversal of soft tissue anesthesia and the associated functional deficits resulting from intraoral submucosal injections of local anesthetics</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Phenoxybenzamine
<list list-type="bullet"><list-item><p>Pheochromocytoma: Treatment of sweating and hypertension associated with the condition</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Off-label Uses</bold>
</p>
        <p>
<bold>Specific Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tamsulosin:
<list list-type="bullet"><list-item><p>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in males</p></list-item><list-item><p>Lower urinary tract symptoms (LUTS) in males</p></list-item><list-item><p>Ureteral calculi expulsion</p></list-item><list-item><p>Ureteral stent-related urinary symptoms, treatment</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Prazosin
<list list-type="bullet"><list-item><p>Post-traumatic stress disorder PTSD related nightmares and sleep disruptions<xref ref-type="bibr" rid="article-17393.r12">[12]</xref></p></list-item><list-item><p>Raynaud phenomenon</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Phentolamine
<list list-type="bullet"><list-item><p>Hypertensive crisis</p></list-item><list-item><p>Extravasation of sympathomimetic vasopressors</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Phenoxybenzamine
<list list-type="bullet"><list-item><p>Hypertensive crisis caused by sympathomimetic amines</p></list-item><list-item><p>Micturition problems associated with neurogenic bladder</p></list-item><list-item><p>Functional outlet obstruction and partial prostate obstruction</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Other Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ureteral calculi (distal)<xref ref-type="bibr" rid="article-17393.r13">[13]</xref>
<list list-type="bullet"><list-item><p>Alfuzosin</p></list-item><list-item><p>Doxazosin</p></list-item><list-item><p>Terazosin</p></list-item><list-item><p>Silodosin</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Alpha-2 Agonists</bold>
</p>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <p>
<bold>Oral&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clonidine
<list list-type="bullet"><list-item><p>Treatment of attention-deficit/hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy&#x000a0;(extended-release tablet)<xref ref-type="bibr" rid="article-17393.r14">[14]</xref></p></list-item><list-item><p>Management of hypertension, but not recommended as first-line treatment, should be avoided in heart failure patients with a reduced ejection fraction of ischemic origin<xref ref-type="bibr" rid="article-17393.r11">[11]</xref><xref ref-type="bibr" rid="article-17393.r15">[15]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Guanfacine
<list list-type="bullet"><list-item><p>Treatment of attention-deficit/hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy&#x000a0;(extended-release tablet)<xref ref-type="bibr" rid="article-17393.r14">[14]</xref></p></list-item><list-item><p>Management of hypertension, not recommended first line, (immediate-release)<xref ref-type="bibr" rid="article-17393.r11">[11]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Methyldopa
<list list-type="bullet"><list-item><p>Management of hypertension, not recommended first line, particular use in pregnancy; may cause positive Coombs test<xref ref-type="bibr" rid="article-17393.r11">[11]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Lofexidine
<list list-type="bullet"><list-item><p>Mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults<xref ref-type="bibr" rid="article-17393.r16">[16]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Tizanidine
<list list-type="bullet"><list-item><p>Management of spasticity; reserve treatment with tizanidine for daily activities and times when relief of spasticity is most improtant<xref ref-type="bibr" rid="article-17393.r17">[17]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Topical&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Brimonidine
<list list-type="bullet"><list-item><p>Topical treatment of persistent (non-transient) erythema of rosacea in adults</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clonidine
<list list-type="bullet"><list-item><p>Continuous epidural administration as adjunctive therapy with opioids for the treatment of severe cancer pain in patients tolerant to or unresponsive to opioids alone; more effective for neuropathic pain and less effective (or possibly ineffective) for somatic or visceral pain<xref ref-type="bibr" rid="article-17393.r18">[18]</xref>&#x000a0;(epidural)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Dexmedetomidine
<list list-type="bullet"><list-item><p>Intensive care unit sedation: Sedation of initially intubated and mechanically ventilated patients during treatment in intensive care settings</p></list-item><list-item><p>Procedural sedation: Procedural sedation before and/or during awake fiberoptic intubation; sedation before and/or during surgical or other procedures of non-intubated patients</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Off-label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clonidine
<list list-type="bullet"><list-item><p>Clozapine-induced sialorrhea</p></list-item><list-item><p>Diagnosis of pheochromocytoma</p></list-item><list-item><p>Growth hormone stimulation test</p></list-item><list-item><p>Opioid withdrawal</p></list-item><list-item><p>Tourette syndrome</p></list-item><list-item><p>Vasomotor symptoms associated with menopause</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Dexmedetomidine
<list list-type="bullet"><list-item><p>Sedation during awake craniotomy</p></list-item><list-item><p>Treatment of shivering</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17393.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>There are two types of alpha-adrenergic receptors; alpha-1 and alpha-2. Both are G-protein coupled receptors (GPCR); however, the downstream effects of the two are different. The alpha-1 receptor is of the Gq type, resulting in activation of phospholipase C, increasing IP3 and DAG, and ultimately increasing the intracellular calcium concentrations leading to smooth muscle contraction and glycogenolysis.<xref ref-type="bibr" rid="article-17393.r19">[19]</xref> The alpha-2 receptor acts as an allosteric inhibitor through Gi function, leading to an inhibition&#x000a0;of adenylyl cyclase, decreasing the formation of intracellular cAMP. &#x000a0;It also leads to a reduced amount of cytoplasmic calcium, which decreases neurotransmitter release and central vasodilation.<xref ref-type="bibr" rid="article-17393.r20">[20]</xref>&#x000a0;Epinephrine and norepinephrine have relatively equal affinities for both types of alpha-receptors, with other drugs used in shock having a higher selectivity for the alpha-1 receptor. &#x000a0;</p>
      </sec>
      <sec id="article-17393.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Administration of alpha-1 receptor agonists is done intravenously through a central line for shock.&#x000a0;In the setting of anaphylaxis, epinephrine administration should be either intramuscular or subcutaneous, not intravenous. Phenylephrine can be administered orally for congestion. Alpha-1 receptor antagonists can be administered orally for refractory hypertension, behavioral modification, and urinary hesitancy. &#x000a0;In the emergent setting, the administration of alpha-1 blockade agents can be via the intravenous route. Alpha-1 antagonists are predominantly administered orally and in the outpatient setting. Alpha-2 agonists can be given orally or intravenously, depending on the setting and requirement. &#x000a0;</p>
      </sec>
      <sec id="article-17393.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects can be related to autonomic response to the systemic changes induced by the agent or to other receptors being antagonized, often those in the beta-adrenergic receptor family. &#x000a0;When ordering an alpha-1 blocker, it is important to be aware and inform the patient of a first-dose effect. With the initial administration of an alpha-1 blocker, systemic vasodilation can lead to a tachycardic response and orthostatic hypotension.<xref ref-type="bibr" rid="article-17393.r21">[21]</xref> This same effect may also occur in the alpha-2 agonist family; however, this is generally less pronounced than in the alpha-1 blockade. The most common adverse effects of alpha-2 receptor agonists are sedation and fatigue.<xref ref-type="bibr" rid="article-17393.r22">[22]</xref> The adverse effects of alpha-1 agonists include hypertension, tachycardia or other dysrhythmias, increased cardiac demand, and subcutaneous ischemia at the site of injection.<xref ref-type="bibr" rid="article-17393.r23">[23]</xref><xref ref-type="bibr" rid="article-17393.r24">[24]</xref></p>
      </sec>
      <sec id="article-17393.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>As with all drugs, the prescriber should account for any previous history of hypersensitivity before the administration. Alpha-1 receptor agonists are contraindicated in patients with the Reynaud phenomenon or closed-angle glaucoma.<xref ref-type="bibr" rid="article-17393.r25">[25]</xref> Epinephrine should not be given subcutaneously in the upper or lower digits, nose, or penis.<xref ref-type="bibr" rid="article-17393.r26">[26]</xref> Alpha-1 agonists given for congestion are contraindicated in the setting of hypertension, tachycardia, or any cardiac history, causing increased demand on the heart. If prescribing an alpha-1 receptor agonist for vasoconstriction, the administration must be through a central line. The main contraindications for the use of an alpha-blocking agent are a history of orthostatic hypotension and concurrent use of phosphodiesterase inhibitors.<xref ref-type="bibr" rid="article-17393.r27">[27]</xref> Contraindications for alpha-2 agonists include concurrent use of phosphodiesterase inhibitors, orthostatic hypotension, and any condition leading to autonomic instability.<xref ref-type="bibr" rid="article-17393.r28">[28]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17393.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring depends on the setting of drug administration.&#x000a0;If the clinician is giving the drug to increase systemic vascular resistance, then the patient should be maintained on continuous telemetry with ideally continuous monitoring of central venous pressure and arterial pressure. During a period of acute illness, the patient and will likely be under close monitoring in general; special consideration is necessary for cardiac rhythm and blood pressure. &#x000a0;If being given for anaphylaxis, the patient should be monitored in a hospital setting for at least ten hours, as anaphylaxis can have a biphasic onset related to the metabolism of the epinephrine.<xref ref-type="bibr" rid="article-17393.r29">[29]</xref> Patients receiving alpha-1 agonists require monitoring for tachyarrhythmias, blood pressure, and other adverse symptoms relative to taking the drug. In patients receiving either alpha-1 blocking agents or alpha-2 agonists, blood pressure and orthostatic hypotension warrant specific attention. &#x000a0;</p>
      </sec>
      <sec id="article-17393.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Alpha-1 receptor agonists taken at toxic doses lead to increased sympathetic tone, which results in tachycardia, early hypertension progressing to hypotension, mydriasis, anxiety,&#x000a0;and increased glycogenolysis. Recent ingestion or asymptomatic patients require observation; if very recent, then activated charcoal may be an option to attempt to prevent the drug from absorbing if the drug was ingested orally. If symptomatic, the patient should be admitted, generally to the intensive care unit.&#x000a0;Symptomatic treatment is the mainstay, with control of the airway, blood pressure, and heart rate. The alpha blockade may be attempted with caution, as well. Once symptoms abate, the patient is considered to have wholly metabolized the drug. The toxicity of alpha-1 blockers and alpha-2 agonists is an unopposed parasympathetic activity, with bradycardia, hypotension, miosis, and sedation. Observation is sufficient in asymptomatic patients. Supportive care is necessary for symptomatic patients. There is no single antidote for either type of toxicities.<xref ref-type="bibr" rid="article-17393.r6">[6]</xref></p>
      </sec>
      <sec id="article-17393.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Alpha-1 agonists are used in the critical care setting to increase systemic vascular resistance are considered high alert drugs and can be very dangerous if used or dosed incorrectly. Clear and concise communication is necessary between the nurse,&#x000a0;pharmacist, and ordering practitioner (physician, nurse, or physician assistant) in these instances to prevent mistakes that can cause morbidity and mortality. Very close continuous monitoring is also necessary for patients receiving these drugs, and many facilities assign these patients a one-to-one nurse staffing. Many local anesthetics are co-formulated with epinephrine as a hemostatic agent, and when injected subcutaneously, this can cause skin necrosis. Special care between physicians, pharmacists, and nurses is necessary to identify the local agents containing epinephrine clearly to prevent unnecessary complications. Many alpha-1 and alpha-2 drugs are used clinically in the emergency department, so clinical staff must be very thorough in medical and social history before ordering these medications. &#x000a0;In patients that are in skilled nursing facilities that are likely fall risks, if given an alpha-1 blocker or alpha-2 agonist, it should be communicated that they should have close monitoring by nursing staff, as well as fall precautions including a bed alarm, bed rails, and a fall mat, due to the risk of orthostatic hypotension. Drugs that affect alpha-receptors, both antagonists and agonists, require an interprofessional team approach to include clinicians, specialists, nurses, and pharmacists, all working as a collaborative interprofessional team, to direct therapy optimally and derive successful results for patients. [Level V]</p>
      </sec>
      <sec id="article-17393.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17393&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17393">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17393/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17393">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17393.s11">
        <title>References</title>
        <ref id="article-17393.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacha</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lat</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>369</fpage>
            <page-range>369-381</page-range>
            <pub-id pub-id-type="pmid">30644586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hendeles</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Nonprescription medications for respiratory symptoms: Facts and marketing fictions.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-176</page-range>
            <pub-id pub-id-type="pmid">29669663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Ara&#x000fa;jo</surname>
                <given-names>LJT</given-names>
              </name>
              <name>
                <surname>Nagaoka</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Borges</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kouyoumdjian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Participation of hepatic &#x003b1;/&#x003b2;-adrenoceptors and AT1 receptors in glucose release and portal hypertensive response induced by adrenaline or angiotensin II.</article-title>
            <source>Braz J Med Biol Res</source>
            <year>2018</year>
            <month>Nov</month>
            <day>14</day>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>e7526</fpage>
            <pub-id pub-id-type="pmid">30462770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>JRU</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A NECESSITY, NOT A SECOND THOUGHT: PRE-OPERATIVE ALPHA-ADRENOCEPTOR BLOCKADE IN PHEOCHROMOCYTOMA PATIENTS.</article-title>
            <source>Endocr Pract</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-201</page-range>
            <pub-id pub-id-type="pmid">30817195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Back</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Augur</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Young-McCaughan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shirley</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Henschel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Litz</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Roache</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Mintz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wachen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>KT</given-names>
              </name>
              <collab>Consortium to Alleviate PTSD</collab>
            </person-group>
            <article-title>Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans.</article-title>
            <source>Contemp Clin Trials</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>73</volume>
            <fpage>8</fpage>
            <page-range>8-15</page-range>
            <pub-id pub-id-type="pmid">30145268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viera</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Hypertension Update: Resistant Hypertension.</article-title>
            <source>FP Essent</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>469</volume>
            <fpage>20</fpage>
            <page-range>20-25</page-range>
            <pub-id pub-id-type="pmid">29863319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detweiler</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Pagadala</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Candelario</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Detweiler</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lutgens</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center.</article-title>
            <source>J Clin Med</source>
            <year>2016</year>
            <month>Dec</month>
            <day>16</day>
            <volume>5</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">27999253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Katic</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2016</year>
            <month>Aug</month>
            <day>18</day>
            <volume>18</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">27828696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Runyon</surname>
                <given-names>BA</given-names>
              </name>
              <collab>AASLD</collab>
            </person-group>
            <article-title>Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.</article-title>
            <source>Hepatology</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>1651</fpage>
            <page-range>1651-3</page-range>
            <pub-id pub-id-type="pmid">23463403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strope</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Saigal</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <collab>Urologic Diseases in America Project</collab>
            </person-group>
            <article-title>Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population.</article-title>
            <source>Urology</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">21601254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>19</issue>
            <fpage>e127</fpage>
            <page-range>e127-e248</page-range>
            <pub-id pub-id-type="pmid">29146535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ursano</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Norwood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pfefferbaum</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pynoos</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Zatzick</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Benedek</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Altshuler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Mellman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moench</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Norquist</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Twemlow</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yager</surname>
                <given-names>J</given-names>
              </name>
              <collab>Work Group on ASD and PTSD</collab>
              <collab>Steering Committee on Practice Guidelines</collab>
            </person-group>
            <article-title>Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder.</article-title>
            <source>Am J Psychiatry</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>161</volume>
            <issue>11 Suppl</issue>
            <fpage>3</fpage>
            <page-range>3-31</page-range>
            <pub-id pub-id-type="pmid">15617511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preminger</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Tiselius</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Assimos</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Alken</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Buck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gallucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knoll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lingeman</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Nakada</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Pearle</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sarica</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>T&#x000fc;rk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>JS</given-names>
              </name>
              <collab>EAU/AUA Nephrolithiasis Guideline Panel</collab>
            </person-group>
            <article-title>2007 guideline for the management of ureteral calculi.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>178</volume>
            <issue>6</issue>
            <fpage>2418</fpage>
            <page-range>2418-34</page-range>
            <pub-id pub-id-type="pmid">17993340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Subcommittee on Attention-Deficit/Hyperactivity Disorder</collab>
              <collab>Steering Committee on Quality Improvement and Management</collab>
              <name>
                <surname>Wolraich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>DuPaul</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Earls</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Ganiats</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Kaplanek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reiff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>128</volume>
            <issue>5</issue>
            <fpage>1007</fpage>
            <page-range>1007-22</page-range>
            <pub-id pub-id-type="pmid">22003063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosendorff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Findeiss</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <collab>American Heart Association, American College of Cardiology, and American Society of Hypertension</collab>
            </person-group>
            <article-title>Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.</article-title>
            <source>J Am Soc Hypertens</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>453</fpage>
            <page-range>453-98</page-range>
            <pub-id pub-id-type="pmid">25840695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lingford-Hughes</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nutt</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>British Association for Psychopharmacology, Expert Reviewers Group</collab>
            </person-group>
            <article-title>BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.</article-title>
            <source>J Psychopharmacol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>899</fpage>
            <page-range>899-952</page-range>
            <pub-id pub-id-type="pmid">22628390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society</collab>
              <name>
                <surname>Delgado</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aisen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ashwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fehlings</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Shrader</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Tilton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vargus-Adams</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Jan</month>
            <day>26</day>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>336</fpage>
            <page-range>336-43</page-range>
            <pub-id pub-id-type="pmid">20101040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lundblad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trifa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaabachi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ben Khalifa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fekih Hassen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Engelhardt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eksborg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>L&#x000f6;nnqvist</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Alpha-2 adrenoceptor agonists as adjuncts to peripheral nerve blocks in children: a meta-analysis.</article-title>
            <source>Paediatr Anaesth</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>232</fpage>
            <page-range>232-8</page-range>
            <pub-id pub-id-type="pmid">26671834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biazi</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Frasson</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Miksza</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>de Morais</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Fatima Silva</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bertolini</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>de Souza</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Decreased hepatic response to glucagon, adrenergic agonists, and cAMP in glycogenolysis, gluconeogenesis, and glycolysis in tumor-bearing rats.</article-title>
            <source>J Cell Biochem</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>119</volume>
            <issue>9</issue>
            <fpage>7300</fpage>
            <page-range>7300-7309</page-range>
            <pub-id pub-id-type="pmid">29761924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durkee</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Covelo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lines</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kofuji</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Araque</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>G<sub>i/o</sub> protein-coupled receptors inhibit neurons but activate astrocytes and stimulate gliotransmission.</article-title>
            <source>Glia</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1076</fpage>
            <page-range>1076-1093</page-range>
            <pub-id pub-id-type="pmid">30801845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.</article-title>
            <source>J Urol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>195</volume>
            <issue>6</issue>
            <fpage>1825</fpage>
            <page-range>1825-9</page-range>
            <pub-id pub-id-type="pmid">26678956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasseur</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Houdas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harries</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Emul</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Systemic and Local Pharmacokinetics of Clonidine Mucoadhesive Buccal Tablets with Reference Clonidine Oral Tablets in Healthy Volunteers: An Open-Label Randomised Cross-Over Trial.</article-title>
            <source>Adv Ther</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>2022</fpage>
            <page-range>2022-2032</page-range>
            <pub-id pub-id-type="pmid">28726169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nawrocki</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Poremba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lawner</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Push Dose Epinephrine Use in the Management of Hypotension During Critical Care Transport.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-195</page-range>
            <pub-id pub-id-type="pmid">30808241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nah</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>A Prospective, Comparative Study of the Pain of Local Anesthesia Using 2% Lidocaine, 2% Lidocaine With Epinephrine, and 2% Lidocaine With Epinephrine-Bupivicaine Mixture for Eyelid Surgery.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2017</year>
            <season>Mar/Apr</season>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-135</page-range>
            <pub-id pub-id-type="pmid">26974418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayd&#x00131;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tugcu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Toxicological assessment of epinephrine and norepinephrine by analog approach.</article-title>
            <source>Food Chem Toxicol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>118</volume>
            <fpage>726</fpage>
            <page-range>726-732</page-range>
            <pub-id pub-id-type="pmid">29913233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fritz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pohlemann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Accidental Thumb Injection With an Epinephrine Autoinjector.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2017</year>
            <month>Nov</month>
            <day>24</day>
            <volume>114</volume>
            <issue>47</issue>
            <fpage>804</fpage>
            <pub-id pub-id-type="pmid">29229045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pa&#x0015b;ko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodacki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Domaga&#x00142;a-Rodacka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Owczarek</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>83</volume>
            <fpage>1141</fpage>
            <page-range>1141-1145</page-range>
            <pub-id pub-id-type="pmid">27551761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Norman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nappe</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <chapter-title>Alpha Receptor Agonist Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">29763199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17393.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Duration of Observation for Detecting a Biphasic Reaction in Anaphylaxis: A Meta-Analysis.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2019</year>
            <volume>179</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-36</page-range>
            <pub-id pub-id-type="pmid">30763927</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
